Other

Cash Equivalents, Debt and Equity Securities, Unrealized Loss

Vertex Pharmaceuticals Cash Equivalents, Debt and Equity Securities, Unrealized Loss increased by 97.8% to $17.80M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 56.2%, from $40.60M to $17.80M. Over 2 years (FY 2023 to FY 2025), Cash Equivalents, Debt and Equity Securities, Unrealized Loss shows a downward trend with a -45.0% CAGR.

Analysis

StatementBalance Sheet Statement
SectionOther
First reportedQ4 2023
Last reportedQ1 2026
Metric ID: other_cash_equivalents_debt_and_equity_securities_unreal_e23589

Historical Data

10 periods
 Q4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Value$29.70M$47.80M$64.90M$40.20M$49.10M$40.60M$33.30M$16.40M$9.00M$17.80M
QoQ Change—+60.9%+35.8%-38.1%+22.1%-17.3%-18.0%-50.8%-45.1%+97.8%
YoY Change————+65.3%-15.1%-48.7%-59.2%-81.7%-56.2%
Range$9.00M – $64.90M
CAGR-20.4%
Avg YoY Growth-32.6%
Median YoY Growth-52.4%

Frequently Asked Questions

What is Vertex Pharmaceuticals's cash equivalents, debt and equity securities, unrealized loss?
Vertex Pharmaceuticals (VRTX) reported cash equivalents, debt and equity securities, unrealized loss of $17.80M in Q1 2026.
How has Vertex Pharmaceuticals's cash equivalents, debt and equity securities, unrealized loss changed year-over-year?
Vertex Pharmaceuticals's cash equivalents, debt and equity securities, unrealized loss decreased by 56.2% year-over-year, from $40.60M to $17.80M.
What is the long-term trend for Vertex Pharmaceuticals's cash equivalents, debt and equity securities, unrealized loss?
Over 2 years (2023 to 2025), Vertex Pharmaceuticals's cash equivalents, debt and equity securities, unrealized loss has grown at a -45.0% compound annual growth rate (CAGR), from $29.70M to $9.00M.